Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Feb;79(2):330-6.
doi: 10.1111/bcp.12506.

Proton pump inhibitors do not impair the effectiveness of metformin in patients with diabetes

James Flory  1 , Kevin Haynes, Charles E Leonard, Sean Hennessy
Affiliations

Proton pump inhibitors do not impair the effectiveness of metformin in patients with diabetes

James Flory et al. Br J Clin Pharmacol. 2015 Feb.

Abstract

Aims: In order to exert its pharmacodynamic effect, the diabetes drug metformin needs to be taken up into hepatocytes by the organic cation transporter (OCT) system. A recent in vitro study found that proton pump inhibitors (PPIs) inhibit OCT1, OCT2 and OCT3, suggesting that PPIs might reduce metformin's effectiveness. This pharmacoepidemiologic study looked for evidence of a clinical effect of such an interaction.

Methods: This was an observational cohort study examining changes in glycosylated haemoglobin (HbA1c) with exposure to metformin and to PPIs as single agents and in combination. The aim was to assess evidence of a deleterious drug-drug interaction.

Results: PPIs did not reduce the effectiveness of metformin, and indeed were associated with a minimally better glycaemic response by - 0.06 HbA1c percentage points (95% confidence interval, -0.10, -0.01) in metformin initiators.

Conclusions: Despite a mechanistic basis for a potential drug-drug interaction, we found no evidence of a deleterious interaction between PPIs and metformin.

Keywords: HbA1c; diabetes; drug-drug interaction; glucose; metformin; proton pump inhibitor.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Unadjusted HbA1c over time with metformin exposure with background PPI exposure (dotted blue line) and without (solid red line). Shading of boxes is proportional to frequency of HbA1c checks per month
See this image and copyright information in PMC

References

    1. Nies AT, Hofmann U, Resch C, Schaeffeler E, Rius M, Schwab M. Proton pump inhibitors inhibit metformin uptake by organic cation transporters (OCTs) PLoS One. 2011;6:e22163. - PMC - PubMed
    1. Ogawa R, Echizen H. Drug−drug interaction profiles of proton pump inhibitors. Clin Pharmacokinet. 2010;49:509–533. - PubMed
    1. Blume H, Donath F, Warnke A, Schug BS. Pharmacokinetic drug interaction profiles of proton pump inhibitors. Drug Saf. 2006;29:769–784. - PubMed
    1. Gong L, Goswami S, Giacomini KM, Altman RB, Klein TE. Metformin pathways: pharmacokinetics and pharmacodynamics. Pharmacogenet Genomics. 2012;22:820–827. - PMC - PubMed
    1. Wang DS, Jonker JW, Kato Y, Kusuhara H, Schinkel AH, Sugiyama Y. Involvement of organic cation transporter 1 in hepatic and intestinal distribution of metformin. J Pharmacol Exp Ther. 2002;302:510–515. - PubMed

Publication types

MeSH terms

Substances